Stable Angina
Conditions
Brief summary
Treatments for stable angina includes drug therapy such as calcium-channel blocker, beta blocker, and ACEI/ARB. To obtain good prognosis in patients with coronary artery disease,preventing or correcting the progression of atherosclerosis and dyslipidemia is more important than relieving angina symptom. Dysfunction of microvessel is one of the most important factor in patients with coronary artery disease. Recently, we developed the new non-invasive method of evaluating the microvessel in fundus. With this methods, we will compare the effect of each drug (beta blocker, CCB, ARB).
Interventions
DRUGDiltiazem treated group
Diltiazem 180mg for 9 months
DRUGBisoprolol treated group
Bisoprolol 5mg for 9 months
DRUGCandesartan treated group
Candesartan 32mg for 9 months
Sponsors
Seoul National University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
30 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Stable angina patients whose coronary lesions is confirmed by angiography or receives PCI * Unstable Angina/NSTEMI patients who completed PCI for main lesions * Either systolic \> 130mmHg or diastolic \> 80mmHg, or patients with anti-hypertensive drugs
Exclusion criteria
* STEMI patients within one month * Variant Angina * Liver function abnormality or renal failure * History of Hypersensitivity to testing drugs * Severe heart failure(NYHA class\>3) or uncorrectable hematologic disease * Woman possible to be pregnant * Uncontrolled diabetes * Expected life span \< one year
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Wall to lumen ratio of fundus vessel | baseline, 9 months | Measurement of change in the ratio of wall thickness to lumen of the fundus vessel from baseline to 9 month follow up |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| lipid parameter | baseline, 9 months | Measurement of change in total cholesterol, triglyceride, LDL, small dense LDL, and HDL |
| Serum markers of inflammation | baseline, 9 months | CRP |
| Change of nitrate need | baseline, 1 months, and 3 months | Measure of change of nitrate need |
Countries
South Korea
Contacts
Primary ContactHae-Young Lee, MD, PhD
Backup ContactHyo-Soo Kim, MD, PhD
Outcome results
None listed